Verona logo.jpg
Verona Pharma to Present at 43rd Annual Canaccord Growth Conference
26 juil. 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona logo.jpg
Verona Pharma to Report Second Quarter 2023 Financial Results and Provide Corporate Update
20 juil. 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., July 20, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Publication of Phase 3 ENHANCE Data in the American Journal of Respiratory and Critical Care Medicine
28 juin 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., June 28, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces the American Journal of Respiratory and Critical Care...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Submits New Drug Application to US FDA for Ensifentrine for the Maintenance Treatment of COPD
27 juin 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., June 27, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces the submission of a New Drug Application (“NDA”) to the US...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at Jefferies Healthcare Conference
24 mai 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., May 24, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports First Quarter 2023 Financial Results and Provides Corporate Update
09 mai 2023 02h00 HE | Verona Pharma plc
NDA submission on schedule for Q2 2023 12 abstracts and one symposium expanding on successful Phase 3 ENHANCE data to be presented at American Thoracic Society 2023 Strong balance sheet to support...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
02 mai 2023 02h00 HE | Verona Pharma plc
12 Abstracts and one Symposium further support potential of ensifentrine,a first-in-class, selective, dual inhibitor of PDE3 and PDE4 Conference call May 23 at 4:00 p.m. EDT / 9:00 p.m. BST LONDON...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
25 avr. 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Nuance Pharma Announces Dosing of First Patient in ENHANCE – China Phase 3 Trial for COPD
10 avr. 2023 02h00 HE | Verona Pharma plc
LONDON and RALEIGH, N.C., April 10, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
07 mars 2023 02h00 HE | Verona Pharma plc
Transformational results in Phase 3 ENHANCE program for COPD NDA submission expected Q2 2023 Strong balance sheet to support planned US commercial launch Conference call today at 9:00 a.m. EST /...